Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Picard Medical, Inc. ( (PMI) ) just unveiled an announcement.
On December 18, 2025, Picard Medical, Inc. announced that its management team would ring the New York Stock Exchange opening bell that same day to commemorate the company’s transition to the public markets and highlight its ongoing work in total artificial heart therapy for end-stage heart failure patients. The ceremony underscores Picard Medical’s move into a new phase of growth as a newly public company, with executives emphasizing that public-market access is expected to support further development of its artificial heart platform, including the fully implantable Emperor system, and to build on its long-standing clinical leadership in mechanical circulatory support, signaling potential long-term benefits for patients, hospital partners and investors focused on advanced cardiac technologies.
More about Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems LLC, a Tucson, Arizona–based medical device maker that develops, manufactures and commercializes the SynCardia Total Artificial Heart, an implantable system that fully replaces the function of a failing human heart for patients with end-stage heart failure. SynCardia’s device is the first total artificial heart approved by both the U.S. Food and Drug Administration and Health Canada, is the only commercially available artificial heart in the United States and Canada, and has been implanted more than 2,100 times at hospitals in 27 countries, making it the most widely used and extensively studied artificial heart globally.
Average Trading Volume: 2,351,418
For detailed information about PMI stock, go to TipRanks’ Stock Analysis page.